Tissue Analysis After Tumor Ablation for Liver Metastases Leading to Immediate Retreatment

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

October 25, 2019

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions
Liver Metastases
Interventions
DIAGNOSTIC_TEST

[18-F]- FDG - PET

Patients will undergo a limited non-contrast CT and first injection PET to localize the lesion

PROCEDURE

Tumor ablation (TA)

Standard ablation with the intent to create a radius of ablation at least 10 mm larger than the largest lesion diameter in order to achieve a minimum of 5 mm ablation margin around the tumor. Any radiographically-identified and biopsy-confirmed residual tumor will be treated on site with immediate ablation. This repeat ablation is not standard of care but will be performed as described for the initial ablation (in the same procedure session) and follow up will be resumed.

DIAGNOSTIC_TEST

PET/CT Scan

Eligible patients will undergo PET/CT -guided tumor ablation as per standard IR guidelines. All patients will undergo PET/CT again, within approximately 6 weeks (+/- 2 weeks) of tumor ablation to evaluate for CN in the target tumor(s) or any sign of residual tissue enhancement, representing viable residual tumor and incomplete treatment.

Trial Locations (1)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER